1. Home
  2. MIGI vs TVRD Comparison

MIGI vs TVRD Comparison

Compare MIGI & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mawson Infrastructure Group Inc.

MIGI

Mawson Infrastructure Group Inc.

HOLD

Current Price

$7.41

Market Cap

33.6M

Sector

Finance

ML Signal

HOLD

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$3.09

Market Cap

29.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIGI
TVRD
Founded
2012
2017
Country
United States
United States
Employees
N/A
12
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.6M
29.1M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
MIGI
TVRD
Price
$7.41
$3.09
Analyst Decision
Hold
Buy
Analyst Count
1
7
Target Price
N/A
$29.50
AVG Volume (30 Days)
1.2M
49.0K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$39,754,085.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$2.75
52 Week High
$15.80
$43.65

Technical Indicators

Market Signals
Indicator
MIGI
TVRD
Relative Strength Index (RSI) 73.98 44.85
Support Level $3.95 $2.75
Resistance Level $15.80 $3.50
Average True Range (ATR) 1.06 0.24
MACD 0.22 0.02
Stochastic Oscillator 99.79 45.33

Price Performance

Historical Comparison
MIGI
TVRD

About MIGI Mawson Infrastructure Group Inc.

Mawson Infrastructure Group Inc is focused on digital infrastructure platforms. It designs, builds and operates next-generation digital infrastructure platforms for enterprise customers and for its own purposes. The company provides services spanning AI, HPC, digital assets including Bitcoin mining, and other intensive compute applications. The company delivers both self-mining operations and colocation services to enterprise customers with a vertically integrated infrastructure model built for scalability and efficiency. The company also has an energy management business, which utilizes software and analysis, to generate revenue by participating in energy management programs. It operates as one energy management and digital asset mining segment.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: